TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9924277

Group type: EXPERIMENTAL
Intervention: Tomato purée (16.5 mg total lycopene)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fresh raw tomato (16.5 mg total lycopene)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily dietary portions of tomato purée (16.5 mg total lycopene) for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily dietary portions of fresh raw tomato (16.5 mg total lycopene) for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tomato purée
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fresh raw tomato
Number of subjects: 10
Study: 8000625

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 301
Study: 2682096

Group type: EXPERIMENTAL
Intervention: 4 g mezlocillin and 0.5 g metronidazole (one-shot dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Short-time prophylaxis (2 days)
Number of subjects: 90
Study: 782698

Group type: EXPERIMENTAL
Intervention: BCNU (NSC-409962)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: BCNU maintenance therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 47
Study: 28493413

Group type: EXPERIMENTAL
Intervention: Family environment, network, parental socio‐economic status, self‐efficacy, proactive personality
Number of subjects: 250
Study: 29025506

Group type: EXPERIMENTAL
Intervention: ENRICH program (8-week face-to-face intervention)
Number of subjects: 60
Study: 25840952

Group type: EXPERIMENTAL
Intervention: Abnormal left ventricular geometry (LVG)
Number of subjects: 1961
Study: 22230353

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate‐electrolyte solution (CHO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Electrolyte solution (PL)
Number of subjects: 15
Study: 20049949

Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation of mesalamine at 2.4 g/day
Number of subjects: 131

Group type: COMPARATOR
Intervention: Time-dependent release formulation of mesalamine at 2.25 g/day
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation of mesalamine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Time-dependent release formulation of mesalamine
Number of subjects: 131
Study: 19265453

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine 3 d (AL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: artesunate monotherapy 7 d (AS7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 0
Study: 15726272

Group type: EXPERIMENTAL
Intervention: Peripheral repetitive magnetic stimulation (rMS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 53
Study: 12093428

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented total parenteral nutrition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control nutrition (isonitrogenous, isoenergetic)
Number of subjects: 84
Study: 15613202

Group type: EXPERIMENTAL
Intervention: Relaxation imagery techniques
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional pharmacotherapy
Number of subjects: 10
Study: 7555918

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 30
Study: 2028366

Group type: EXPERIMENTAL
Intervention: 21-day tetracycline regimen
Number of subjects: 918

Group type: COMPARATOR
Intervention: 7-day tetracycline regimen
Number of subjects: 918
Study: 7081179

Group type: EXPERIMENTAL
Intervention: Dilatation and antireflux surgery (Group I, 20 patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dilatation plus medical management (Group II, 18 patients)
Number of subjects: 38
Study: 31899379

Group type: EXPERIMENTAL
Intervention: Photoactivated disinfection (PAD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salvadora persica (SP) gel application
Number of subjects: 25

Group type: COMPARATOR
Intervention: Professionally administered plaque removal (PAPR)
Number of subjects: 25
Study: 31270101

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.2 (THS)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Continued smoking of preferred cigarette brand
Number of subjects: 984
Study: 28317086

Group type: EXPERIMENTAL
Intervention: Group Support Psychotherapy (GSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group HIV education
Number of subjects: 0
Study: 26159015

Group type: EXPERIMENTAL
Intervention: Qingfei Decoction (QD) treatment group
Number of subjects: 48
Study: 24631099

Group type: EXPERIMENTAL
Intervention: Automated reminder messages for vaccine doses two and three
Number of subjects: 365

Group type: COMPARATOR
Intervention: Routine follow-up (control)
Number of subjects: 365
Study: 23066765

Group type: EXPERIMENTAL
Intervention: Discharge Preparation Program (DPP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual rehabilitation program (Control)
Number of subjects: 49
Study: 19776405

Group type: EXPERIMENTAL
Intervention: Escalated dose of daunorubicin (90 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Conventional dose of daunorubicin (45 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Number of subjects: 813
Study: 17096464

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Clinical case management
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both cognitive-behavioral group therapy and clinical case management
Number of subjects: 67
Study: 16793780

Group type: EXPERIMENTAL
Intervention: 30-min break
Number of subjects: 30

Group type: COMPARATOR
Intervention: No break (Control)
Number of subjects: 30
Study: 12631177

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMP) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional flap debridement with ICI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional flap debridement with RBI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional flap debridement (both ICI and RBI)
Number of subjects: 20
Study: 11085964

Group type: EXPERIMENTAL
Intervention: Acetylcholine (intra-arterial infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium nitroprusside (exogenous nitric oxide donor)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Verapamil (calcium channel blocker)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitroglycerin (sublingual administration)
Number of subjects: 8
Study: 8857879

Group type: EXPERIMENTAL
Intervention: Indwelling percutaneous intramuscular electrode composed of helically coiled Teflon‐coated rope stranded from 19 hard drawn wires of SUS 316L stainless steel (SES 114)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Indwelling percutaneous intramuscular electrode
Number of subjects: 17
Study: 1352732

Group type: EXPERIMENTAL
Intervention: Esmolol (2 or 3 mg.kg-1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Esmolol (3 mg.kg-1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Esmolol and topical laryngeal anaesthesia
Number of subjects: 27
Study: 6144933

Group type: EXPERIMENTAL
Intervention: Screened with modern mammography
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Not screened (unscreened subjects)
Number of subjects: 30000
Study: 30361250

Group type: EXPERIMENTAL
Intervention: Sertraline 25‐100 mg (titrated upwards over 9 days)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Sertraline and Placebo
Number of subjects: 223
Study: 28916591

Group type: EXPERIMENTAL
Intervention: Computer-guided glucose infusion rate (GIR) with continuous glucose monitoring (CGM)
Number of subjects: 50
Study: 25792176

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Magnesium 30 mg/kg
Number of subjects: 30
Study: 23385272

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection plus physiotherapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo injection plus physiotherapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: No physiotherapy
Number of subjects: 165
Study: 21300192

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study: 19483418

Group type: EXPERIMENTAL
Intervention: Reduced dose of docetaxel (40 or 50 mg/m²)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose of docetaxel (60 mg/m²)
Number of subjects: 0
Study: 17089233

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v. at the end of the operation followed by 8 mg b.i.d., i.v. for 24 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 40
Study: 15041568

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11719730

Group type: EXPERIMENTAL
Intervention: 600 mg oral gemfibrozil twice daily for 2 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg oral gemfibrozil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9322139

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 15
Study: 8432299

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg every 6 h on the first day and 12.5 mg qid on the second day if MAP > or = 70 mmHg (group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 36
Study: 3829592

Group type: EXPERIMENTAL
Intervention: Modified single breath method for estimation of cardiac output
Number of subjects: 100
Study: 30617247

Group type: EXPERIMENTAL
Intervention: Postoperative hypersensitive C-reactive protein (hs-CRP) levels
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Postoperative homocysteine (HCY) levels
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Coronary bifurcation lesions
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Stent length
Number of subjects: 1132
Study: 28699550

Group type: EXPERIMENTAL
Intervention: Community engagement intervention
Number of subjects: 12312

Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 12312
Study: 26044829

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 97
Study: 22738092

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Total intravenous-plus-oral regimen (LEV)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Total intravenous-plus-oral regimen (PHT)
Number of subjects: 81
Study: 21705281

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 or 15 mg/kg intravenously (I.V.) on day 1, every 21 days plus investigator's choice of agents (pemetrexed, docetaxel, or erlotinib) for second-line and subsequent lines of treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator's choice of agents alone indicated for use in second-line and subsequent lines of treatment, but no further bevacizumab treatment.
Number of subjects: 0
Study: 18562414

Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin reuptake inhibitor)
Number of subjects: 20
Study: 16406721

Group type: EXPERIMENTAL
Intervention: Aerosolised hyaluronic acid (HA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study: 14640845

Group type: EXPERIMENTAL
Intervention: Central words (personally significant items)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral words (task-relevant items)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral words (personally significant items)
Number of subjects: 0
Study: 12922956

Group type: EXPERIMENTAL
Intervention: Combination therapy including glucocorticoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine alone (COBRA trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment (2001 cohort with early RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 0
Study: 10689835

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (droperidol and fentanyl)
Number of subjects: 40
Study: 8638787

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg IV 15 min after skin incision
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 30
Study: 1999742

Group type: EXPERIMENTAL
Intervention: Advice only
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Brief patient-centered counseling
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Counseling plus prescription of nicotine-containing gum (Nicorette)
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Telephone counseling
Number of subjects: 1286
Study: 6234279

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 40
Study: 31504608

Group type: COMPARATOR
Intervention: No supplemental VE (CON)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 25 IU/kg dry matter (LOW)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 500 IU per steer daily (MED)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 1,000 IU per steer daily (HIGH)
Number of subjects: 204
Study: 30133134

Group type: EXPERIMENTAL
Intervention: Cinnamyl Isobutyrate (CIB) 0.45 mg in 75 g glucose solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (75 g glucose solution)
Number of subjects: 26
Study: 26740346

Group type: EXPERIMENTAL
Intervention: 6-hour group structured education programme with annual refresher course and regular phone contact
Number of subjects: 880

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 880
Study: 25129333

Group type: EXPERIMENTAL
Intervention: Biomarkers analyzed using a point‐of‐care device in the ambulance
Number of subjects: 480

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 480
Study: 23185753

Group type: EXPERIMENTAL
Intervention: Fuzheng Jianpi Decoction (FJD) combined with chemotherapy
Number of subjects: 167
Study: 20605898

Group type: EXPERIMENTAL
Intervention: Exercise combined with caloric restriction (EX + CR); caloric restriction of 20-35% below baseline energy requirements, supervised training sessions 4 times per week, 30-60 min at moderate intensity
Number of subjects: 33

Group type: COMPARATOR
Intervention: Light conditioning (LC); eucaloric diet, supervised training sessions 2 times per week, 30-60 min at moderate intensity
Number of subjects: 33
Study: 18019991

Group type: EXPERIMENTAL
Intervention: Knowles pinning
Number of subjects: 62

Group type: COMPARATOR
Intervention: Plating
Number of subjects: 62
Study: 16261956

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1 mg/dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 26
Study: 12297711

Group type: EXPERIMENTAL
Intervention: Thermal balloon endometrial ablation therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gestagen therapy
Number of subjects: 26
Study: 10225243

Group type: EXPERIMENTAL
Intervention: Smoking-cessation intervention (12 intensive sessions with behavior modification and nicotine chewing gum)
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual-care group (advised to stop smoking)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Intervention groups (smoking cessation)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Continuous smokers
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Respiratory symptoms
Number of subjects: 5887
Study: 7602060

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (IFN-alpha 2a) at an induction dose of 6 MIU thrice weekly for 3 months, followed by 3 MIU thrice weekly for an additional 3 months as maintenance therapy.
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (IFN-alpha 2a)
Number of subjects: 1831
Study: 1693732

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 227340

Group type: EXPERIMENTAL
Intervention: Long-acting fluphenazine decanoate with social therapy (ST)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Long-acting fluphenazine decanoate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral fluphenazine hydrochloride
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 105
Study: 28760696

Group type: EXPERIMENTAL
Intervention: Simulation training (4 sessions over 12 months)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (status quo, no training)
Number of subjects: 157
Study: 26406319

Group type: EXPERIMENTAL
Intervention: Working memory training group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 31
Study: 23446733

Group type: EXPERIMENTAL
Intervention: Water-based exercise (WE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Land-based exercise (LE)
Number of subjects: 14
Study: 21504540

Group type: EXPERIMENTAL
Intervention: BioAggregate (BA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA-A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA-PR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 28
Study: 18070199

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 111
Study: 16825841

Group type: EXPERIMENTAL
Intervention: Tai-Chi exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-help program
Number of subjects: 50
Study: 12766742

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (RV)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 33
Study: 11417777

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intranasal nicotine spray
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Inhaled nicotine
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nicotine sublingual tablet
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 4-mg gum
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 94
Study: 9327189

Group type: EXPERIMENTAL
Intervention: soluble aspirin
Number of subjects: 12

Group type: COMPARATOR
Intervention: plain aspirin
Number of subjects: 12

Group type: COMPARATOR
Intervention: enteric-coated aspirin granules
Number of subjects: 12

Group type: COMPARATOR
Intervention: mouth-dispersible aspirin
Number of subjects: 12
Study: 7942531

Group type: EXPERIMENTAL
Intervention: Cocaine abusers in group 1 (rehabilitation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cocaine abusers in group 2 (emergency room)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cocaine abusers in group 3 (sudden death)
Number of subjects: 200
Study: 3259087

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg intravenous bolus for induction and 0.1 mg/kg/minute continuous infusion for maintenance
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ketamine 1.5 mg/kg intravenous bolus for induction and 50 micrograms/kg/minute continuous infusion for maintenance
Number of subjects: 16
Study: 1908080

Group type: COMPARATOR
Intervention: Nicotine gum at $20/box
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nicotine gum at $6/box
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nicotine gum at $0/box
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nicotine gum (all price groups)
Number of subjects: 106
Study: 22297

Group type: EXPERIMENTAL
Intervention: Pindolol administered before bronchoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 31885286

Group type: EXPERIMENTAL
Intervention: Carbon monoxide islets (islets harvested in a carbon monoxide-saturated medium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (islets harvested in a normal medium)
Number of subjects: 0
Study: 28162818

Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition
Number of subjects: 71

Group type: COMPARATOR
Intervention: No preoperative immunonutrition (Control)
Number of subjects: 71
Study: 26438108

Group type: EXPERIMENTAL
Intervention: Active coil group (rTMS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 36
Study: 22858559

Group type: EXPERIMENTAL
Intervention: Phased ipilimumab
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Concurrent ipilimumab
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 130
Study: 21452932

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy and radiotherapy
Number of subjects: 120
Study: 19728936

Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injections (80 mg of methylprednisolone with 3 ml of 2% plain xylocaine and 3 ml of normal saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative management (bed rest, non-steroidal anti-inflammatory agents, muscle relaxants, and opioids)
Number of subjects: 50